Get the Stockscreener App
1.03
0.96%
-0.01
After Hours:
1.05
0.02
+1.94%
Standard Biotools Inc stock is traded at $1.03, with a volume of 1.15M.
It is down -0.96% in the last 24 hours and up +9.32% over the past month.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
See More
Previous Close:
$1.04
Open:
$1.03
24h Volume:
1.15M
Relative Volume:
0.46
Market Cap:
$402.08M
Revenue:
$86.26M
Net Income/Loss:
$-50.08M
P/E Ratio:
-4.2058
EPS:
-0.2449
Net Cash Flow:
$-94.48M
1W Performance:
+4.59%
1M Performance:
+9.32%
6M Performance:
-25.36%
1Y Performance:
+7.91%
1-Day Range:
$1.015
$1.056
1-Week Range:
$0.9706
$1.06
52-Week Range:
$0.8701
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Name
Standard Biotools Inc
Sector
Industry
Phone
(650) 266-6000
Address
50 MILK STREET, BOSTON
Compare LAB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
1.03 | 405.98M | 86.26M | -50.08M | -94.48M | -0.2449 |
ABT
Abbott Laboratories
|
87.41 | 152.88B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
316.48 | 120.18B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.60 | 100.34B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.78 | 84.95B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.78 | 47.91B | 6.30B | 1.07B | 1.09B | 1.8406 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-27-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-16-24 | Initiated | TD Cowen | Buy |
| Apr-04-24 | Initiated | Jefferies | Buy |
| Jul-12-23 | Initiated | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Stock (LAB) Latest News
STANDARD BIOTOOLS (LAB) CFO has 18,871 shares withheld for RSU taxes - Stock Titan
Standard Biotools (LAB) SVP has 25,729 shares withheld for taxes - Stock Titan
STANDARD BIOTOOLS (LAB) CEO has shares withheld to cover RSU tax obligations - Stock Titan
Standard BioTools Q1 2026 Earnings: Massive EPS Beat Fails to Lift Shares Amid Revenue UncertaintyProfit Announcement - Newser
DKSH : and Standard BioTools Announce Distribution Partnership to Expand Spatial Biology and Proteomics Solutions in Australia and New Zealand - marketscreener.com
Standard BioTools (LAB) Q1 2026 Earnings: $0.33 EPS Surges Past $-0.06 EstimatesStock Idea Hub - Newser
Standard BioTools (LAB) Q1 2026 Earnings Surprise: EPS $0.33, Up SignificantCrowd Consensus Signals - Newser
SomaLogic stock (US82489T1043): merger with Standard BioTools reshapes proteomics player - AD HOC NEWS
SomaLogic Inc stock (US82489T1043): Illumina merger closes and reshapes proteomics story - AD HOC NEWS
MAK Capital (NASDAQ: LAB) reports 6.7% stake in Standard BioTools - Stock Titan
Viking Global (LAB) holds 58.65M shares (~15%) of Standard BioTools - Stock Titan
Should You Sell Standard BioTools (LAB) After -1.52% Drop? 2026-05-15Collaborative Trading Signals - Newser
Standard BioTools (LAB) Q1 2026 Earnings: Why the Beat MattersBinary Event - newser.com
SomaLogic stock (US82489T1043): Completed $350M sale to Illumina - AD HOC NEWS
MSN Money - MSN
Standard BioTools (LAB) reports Q1 loss, tops revenue estimates - MSN
Standard BioTools Inc. (LAB) Stock Analysis: A 55% Potential Upside Beckons Investors - DirectorsTalk Interviews
Standard Biotools Faces Nasdaq Delisting Risk After Prolonged Sub-$1 Share Price - TipRanks
Number of shareholders of Standard BioTools Inc. – NASDAQ:LAB - TradingView
Standard BioTools (NASDAQ: LAB) posts Q1 2026 profit on SomaScan sale windfall - Stock Titan
Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry - MSN
LAB Financials: Income Statement, Balance Sheet & Cash Flow | STANDARD BIOTOOLS INC - Stock Titan
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Standard BioTools: Q1 Earnings Snapshot - marketscreener.com
Standard BioTools Highlights Improved Q1 2026 Results, Outlook - TipRanks
Standard BioTools 1Q Loss $14.6M >LAB - Moomoo
Standard BioTools 1Q Rev $21.1M >LAB - Moomoo
Standard BioTools ends quarter with $524M as loss shrinks 54% - Stock Titan
Standard BioTools (LAB) Q1 2026 results show big cash boost and EBITDA gains - Stock Titan
Standard BioTools Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Standard BioTools Reports First Quarter 2026 Financial Results - ChartMill
Standard BioTools posts Q1 2026 revenue growth and narrows losses, aiming for profitability this year - Pluang
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026 - Investing News Network
Standard BioTools Inc expected to post a loss of 6 cents a shareEarnings Preview - TradingView
Standard Biotools Inc Stock (LAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):